178 related articles for article (PubMed ID: 28802891)
1. Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Ammann EM; Shanafelt TD; Larson MC; Wright KB; McDowell BD; Link BK; Chrischilles EA
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e11-e25. PubMed ID: 28802891
[TBL] [Abstract][Full Text] [Related]
2. Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
Ammann EM; Shanafelt TD; Wright KB; McDowell BD; Link BK; Chrischilles EA
Leuk Lymphoma; 2018 Mar; 59(3):643-649. PubMed ID: 28718694
[TBL] [Abstract][Full Text] [Related]
3. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States.
Shenoy PJ; Malik N; Sinha R; Nooka A; Nastoupil LJ; Smith M; Flowers CR
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):498-506. PubMed ID: 21889433
[TBL] [Abstract][Full Text] [Related]
4. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
Elnair R; Ellithi M; Kallam A; Shostrom V; Bociek RG
Ann Hematol; 2021 Oct; 100(10):2513-2519. PubMed ID: 34279675
[TBL] [Abstract][Full Text] [Related]
6. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of older adults with chronic lymphocytic leukemia: A Surveillance, Epidemiology, and End Results-Medicare cohort study.
Duchesneau ED; McNeill AM; Schary W; Pate V; Lund JL
J Geriatr Oncol; 2023 Nov; 14(8):101602. PubMed ID: 37696241
[TBL] [Abstract][Full Text] [Related]
10. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
Satram-Hoang S; Reyes C; Hoang KQ; Momin F; Skettino S
Ann Hematol; 2014 Aug; 93(8):1335-44. PubMed ID: 24638841
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in Taiwan, 2006-2015.
Ko BS; Chen LJ; Huang HH; Chen HM; Hsiao FY
Int J Clin Pract; 2021 Aug; 75(8):e14258. PubMed ID: 33884738
[TBL] [Abstract][Full Text] [Related]
12. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
Huang X; Qiu L; Jin J; Zhou D; Chen X; Hou M; Hu J; Hu Y; Ke X; Li J; Liang Y; Liu T; Lv Y; Ren H; Sun A; Wang J; Zhao C; Salman M; Sun S; Howes A; Wang J; Wu P; Li J
Cancer Med; 2018 Apr; 7(4):1043-1055. PubMed ID: 29533000
[TBL] [Abstract][Full Text] [Related]
14. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
[TBL] [Abstract][Full Text] [Related]
15. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia.
Brewer JD; Shanafelt TD; Call TG; Cerhan JR; Roenigk RK; Weaver AL; Otley CC
Int J Dermatol; 2015 Aug; 54(8):e287-93. PubMed ID: 25772131
[TBL] [Abstract][Full Text] [Related]
16. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.
Maruyama D; Wang C; Tanizawa Y; Cai Z; Huang Y; Tajimi M; Kusumoto S
J Clin Exp Hematop; 2023; 63(4):219-229. PubMed ID: 38148012
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.
Bird ST; Tian F; Flowers N; Przepiorka D; Wang R; Jung TH; Kessler Z; Woods C; Kim B; Miller BW; Wernecke M; Kim C; McKean S; Gelperin K; MaCurdy TE; Kelman JA; Graham DJ
JAMA Oncol; 2020 Feb; 6(2):248-254. PubMed ID: 31855259
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.
Lam CJ; Curtis RE; Dores GM; Engels EA; Caporaso NE; Polliack A; Warren JL; Young HA; Levine PH; Elmi AF; Fraumeni JF; Tucker MA; Morton LM
J Clin Oncol; 2015 Oct; 33(28):3096-104. PubMed ID: 26240221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
